Thomas Ulmer
Direktor/Vorstandsmitglied bei Aravax Pty Ltd.
Profil
Thomas Ulmer is a Non-Executive Director at Aravax Pty Ltd.
He was previously a Co-Managing Director at Immatics Biotechnologies GmbH from 2018 to 2020 and Head of Planning, Forecasting & Resource Allocation at Merck KGaA from 2012 to 2016.
He also served as Chief Financial Officer at Immatics NV.
Ulmer holds an MBA from the University of Giessen.
Aktive Positionen von Thomas Ulmer
Unternehmen | Position | Beginn |
---|---|---|
Aravax Pty Ltd.
Aravax Pty Ltd. BiotechnologyHealth Technology Aravax Pty Ltd. develops treatments for peanut allergies. The company was founded in May 2015 and is headquartered in Melbourne, Australia. | Direktor/Vorstandsmitglied | 01.11.2020 |
Ehemalige bekannte Positionen von Thomas Ulmer
Unternehmen | Position | Ende |
---|---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Vorstandsvorsitzender | 12.02.2020 |
MERCK KGAA | Corporate Officer/Principal | 01.07.2016 |
IMMATICS N.V. | Finanzdirektor/CFO | - |
Ausbildung von Thomas Ulmer
University of Giessen | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
MERCK KGAA | Health Technology |
IMMATICS N.V. | Health Technology |
Private Unternehmen | 2 |
---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Aravax Pty Ltd.
Aravax Pty Ltd. BiotechnologyHealth Technology Aravax Pty Ltd. develops treatments for peanut allergies. The company was founded in May 2015 and is headquartered in Melbourne, Australia. | Health Technology |